Recursion Pharmaceuticals (NASDAQ:RXRX) Cut to Strong Sell at Wall Street Zen

Wall Street Zen lowered shares of Recursion Pharmaceuticals (NASDAQ:RXRX) from a sell rating to a strong sell rating in a report released on Saturday.

A number of other brokerages have also recently issued reports on RXRX. Needham & Company LLC reaffirmed a “buy” rating and issued a $8.00 price objective on shares of Recursion Pharmaceuticals in a research note on Thursday, May 7th. Morgan Stanley lifted their target price on shares of Recursion Pharmaceuticals from $5.00 to $5.50 and gave the stock an “equal weight” rating in a research report on Thursday, May 14th. JPMorgan Chase & Co. lowered their price target on shares of Recursion Pharmaceuticals from $11.00 to $10.00 and set an “overweight” rating for the company in a research note on Thursday, April 30th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research report on Friday, July 17th. Two research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Recursion Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $8.10.

Recursion Pharmaceuticals Stock Performance

NASDAQ:RXRX opened at $3.29 on Friday. The company has a market capitalization of $1.74 billion, a price-to-earnings ratio of -3.16 and a beta of 1.03. The business has a 50 day moving average of $3.31 and a 200 day moving average of $3.44. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.03 and a quick ratio of 5.03. Recursion Pharmaceuticals has a 1-year low of $2.77 and a 1-year high of $7.18.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.01). The business had revenue of $7.67 million for the quarter, compared to the consensus estimate of $10.97 million. Recursion Pharmaceuticals had a negative net margin of 945.94% and a negative return on equity of 50.41%. During the same quarter in the previous year, the business earned ($0.41) earnings per share. On average, sell-side analysts predict that Recursion Pharmaceuticals will post -0.9 earnings per share for the current fiscal year.

Insider Activity at Recursion Pharmaceuticals

In other news, Director Blake Borgeson sold 30,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 4th. The shares were sold at an average price of $3.25, for a total value of $97,500.00. Following the transaction, the director owned 6,188,287 shares in the company, valued at approximately $20,111,932.75. This trade represents a 0.48% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Najat Khan sold 23,588 shares of Recursion Pharmaceuticals stock in a transaction on Friday, June 5th. The stock was sold at an average price of $3.58, for a total transaction of $84,445.04. Following the completion of the transaction, the chief executive officer directly owned 2,175,796 shares in the company, valued at approximately $7,789,349.68. The trade was a 1.07% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 131,937 shares of company stock valued at $478,874 in the last quarter. Corporate insiders own 6.65% of the company’s stock.

Institutional Investors Weigh In On Recursion Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in RXRX. Vanguard Group Inc. increased its position in shares of Recursion Pharmaceuticals by 18.6% in the fourth quarter. Vanguard Group Inc. now owns 47,187,759 shares of the company’s stock valued at $192,998,000 after acquiring an additional 7,407,606 shares during the period. ARK Investment Management LLC boosted its holdings in shares of Recursion Pharmaceuticals by 11.2% during the fourth quarter. ARK Investment Management LLC now owns 37,316,856 shares of the company’s stock worth $152,626,000 after purchasing an additional 3,771,357 shares during the period. State Street Corp grew its stake in shares of Recursion Pharmaceuticals by 38.7% in the fourth quarter. State Street Corp now owns 25,333,888 shares of the company’s stock worth $103,616,000 after purchasing an additional 7,064,963 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Recursion Pharmaceuticals by 13.6% in the fourth quarter. Geode Capital Management LLC now owns 10,934,252 shares of the company’s stock worth $44,731,000 after purchasing an additional 1,310,695 shares during the last quarter. Finally, Norges Bank purchased a new position in Recursion Pharmaceuticals during the 4th quarter valued at about $23,473,000. Hedge funds and other institutional investors own 89.06% of the company’s stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.